Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04582383 · ClinicalTrials.gov registry record · Phase 4

Comparative Effectiveness Study of Spironolactone Versus Doxycycline for Acne

A Phase 4 study of Acne, sponsored by University of Pennsylvania.

Active
Registry status
Phase 4
Development phase
350
Enrollment target
18
Study locations

NCT04582383 is a Phase 4 study of Acne that is active but no longer recruiting, run by University of Pennsylvania. The registered enrollment target is 350 participants, above the 129-participant average among 26 other Acne trials with a reported enrollment target (171% higher). The trial reports 18 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04582383, a Phase 4 study of Acne, is active but no longer recruiting, sponsored by University of Pennsylvania.

ACTIVE NOT RECRUITING
Registry status
Phase 4
Development phase
350 participants
Enrollment target
18
Study locations

Study Summary

Acne is common illness of adolescents and young adults which is associated with substantial morbidity. While topical treatments are often sufficient for mild acne, moderate to severe acne often requires treatment with systemic medications such as oral antibiotics, hormonal therapies such spironolactone, and isotretinoin. Sebum overproduction is fundamental to the pathogenesis of acne with associated disordered keratinization and subsequent microbial colonization and inflammation resulting in the clinical manifestations of acne. Given the influence of hormones on sebum production, therapies that address these underlying hormonal factors such as spironolactone and oral contraceptive pills represent an underutilized treatment option for women with acne and could help decrease the use of long-term oral antibiotics in this patient population. The purpose of this trial is to evaluate the comparative effectiveness of spironolactone versus doxycycline hyclate (tetracycline class antibiotic) for women with acne.

Conditions Studied

Interventions

  • DRUG Spironolactone
  • DRUG Doxycycline Hyclate

Study Locations (18)

Texas

  • Arlington Research Center - Arlington
  • North Texas Center for Clinical Research - Frisco
  • CCS Texas - Houston

California

  • University of California San Francisco - San Francisco
  • Cura Clinical Research - Sherman Oaks

Florida

  • University of Miami - Miami
  • New Horizon Research Center - Miami

New York

  • New York University - New York
  • Northwell Health - North New Hyde Park

Ohio

  • Dermatologists of Central States - Cincinnati
  • Ohio State University Medical Center - Columbus

Oregon

  • Cyn3rgy Research - Gresham
  • Oregon Health and Science University - Portland

Pennsylvania

  • Children's Hospital of Philadelphia - Philadelphia
  • University of Pennsylvania - Philadelphia

Arkansas

  • Johnson Dermatology - Fort Smith

Trial Details

FieldValue
Enrollment Target 350 participants
Start Date 2022-03-30
Est. Completion 2026-07-31
Phase Phase 4

Sponsor

University of Pennsylvania

1,423 total trials

What the Registry Record Tells You About NCT04582383

The ClinicalTrials.gov registry entry for NCT04582383 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 129-participant average among 26 other Acne trials with a reported enrollment target (171% higher). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acne appearing as the primary indexed condition, and to 2 interventions - of which Spironolactone is the first listed.

NCT04582383 reports 18 study locations spanning 10 distinct geographic areas - top geographies include Texas, California, Florida.

Frequently Asked Questions

What is clinical trial NCT04582383 about?

NCT04582383 is a clinical study titled "Comparative Effectiveness Study of Spironolactone Versus Doxycycline for Acne". Acne is common illness of adolescents and young adults which is associated with substantial morbidity. While topical treatments are often sufficient for mild acne, moderate to severe acne often requires treatment with systemic medications such as oral antibiotics, hormonal therapies such spironolact...

What is the current status of trial NCT04582383?

This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 350 participants. The study started on 2022-03-30. Estimated completion is 2026-07-31.

What conditions does trial NCT04582383 study?

This clinical trial studies the following conditions: Acne.

What interventions are being tested in trial NCT04582383?

The interventions under investigation include: Spironolactone (DRUG), Doxycycline Hyclate (DRUG).

Who is sponsoring clinical trial NCT04582383?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04582383 being conducted?

This trial has 18 study locations across Arkansas, California, Florida, Indiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acne

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.